ORTIN GLOBAL LIMITED
ORTIN GLOBAL LIMITED (ORTINGLOBE) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
ortinlabsindia.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 0.05 Cr | 0.04 Cr | 0.01 Cr |
| Operating expenses (approx.) | 0.25 Cr | 0.24 Cr | 0.52 Cr |
| EBITDA | -0.20 Cr | -0.20 Cr | -0.50 Cr |
| OPM % | -445.9% | -511.6% | -3581.4% |
| Other income | 0.04 Cr | 0.04 Cr | 0 Cr |
| Interest | 0.0002 Cr | 0.0004 Cr | 0.0011 Cr |
| Depreciation | 0 Cr | 0 Cr | 0.0001 Cr |
| Profit before tax | -0.16 Cr | -0.16 Cr | -0.50 Cr |
| Tax % | -1.8% | -7.7% | 0.0% |
| Net profit | -0.16 Cr | -0.18 Cr | -0.50 Cr |
| EPS (₹) | ₹-0.20 | ₹-0.22 | ₹-0.62 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 0.34 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1 Cr | Sign in for TTM |
| EBITDA | -0.88 Cr | Sign in for TTM |
| OPM % | -258.2% | Sign in for TTM |
| Other income | 0.04 Cr | Sign in for TTM |
| Interest | 0.0027 Cr | Sign in for TTM |
| Depreciation | 0.01 Cr | Sign in for TTM |
| Profit before tax | -0.84 Cr | Sign in for TTM |
| Tax % | -1.1% | Sign in for TTM |
| Net profit | -0.85 Cr | Sign in for TTM |
| EPS (₹) | ₹-1.04 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 8 Cr |
| Reserves | -6 Cr |
| Borrowings | 0.25 Cr |
| Other liabilities | 2 Cr |
| Total liabilities | 4 Cr |
| Fixed assets (net) | 0.0036 Cr |
| CWIP | — |
| Investments | 0 Cr |
| Inventories | 0.02 Cr |
| Trade receivables | 0.26 Cr |
| Cash & bank | 0.37 Cr |
| Other assets | 3 Cr |
| Total assets | 4 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -0.41 Cr |
| Cash from investing | -0.0036 Cr |
| Cash from financing | 0.33 Cr |
| Net cash flow | -0.09 Cr |
| Free cash flow (OCF − Capex) | -0.41 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -37.5% |
| ROE % | -42.8% |
| Debtor days | 278 |
| Inventory days | 39 |
| Days payable | 84 |
| Cash conversion cycle | 233 |
| Debt / equity | 0.13 |
| Current ratio | 2.39 |
| Net debt / EBITDA | — |
Compare with peers
Loading peers…